A
banner
A

HLA Related- BioMarker Detection

Biomarkers in body fluids or tissues are important indicators of biological states that can provide measurable characteristics of normal or pathogenic processes, and their progression or response to therapy. Testing for these biomarkers allows Transplant Clinics to better define profiles of their patients. Currently available biomarker assays are listed below

Supplier Product Portfolio
One Lambda
  • AT1R – ELISA, Non-HLA Antibodies and AMR? Anti-AT1R antibodies may have an associated risk for Antibody Mediated Rejection. One Lambda now has a solution to detect biomarker antibodies that form against Angiotensin II Type I Receptors (AT1R)

  • C1qScreenTM – Detecting complement-binding antibodies, C1qScreen™ provides a reliable tool for identifying complement binding antibody from non-complement binding antibody
  • Cytokine SSP Genotyping, Research suggests that polymorphic variants of cytokine genes may be associated with acute and chronic transplant rejection. These variants express the corresponding cytokine gene at either elevated or reduced levels. Expression levels of TGF-beta, TNF-alpha, IL-10, IFN Gamma and IL-6 appear to affect the likelihood of organ rejection. Genotyping of these polymorphic variants might be used to further investigate the role of cytokines in organ transplants.

  • KIR SSO Genotyping, Killer Cell Immunoglobulin-Like Receptors (KIR) play an important role in regulating Natural Killer (NK) cell activity. NK cells have been implicated in the promotion of engraftment and mediation of graft-versus-leukemia (GVL). These effects may be the result of donor-recipient HLA epitope mismatching for KIR. The KIR Genotyping Kit identifies the presence or absence of the following genes: 2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DL1, 3DL2, 3DL3, 3DS1, 2DP1, 3DP1, as well as the common variants of 2DL5, 2DS4, and 3DP1. Each tray contains 21 formulations of specific primer sets used to amplify genomic DNA

  • HNA SSP Genotyping One Lambda has developed a genotyping tool using sequence-specific-primer polymerase chain reaction (SSP-PCR) technology to identify known HNA polymorphisms. Human neutrophil antigens (HNA) are involved in a variety of clinical conditions, including immune neutropenias, transfusion related acute lung injury (TRALI), refractoriness to granulocyte transfusions and febrile transfusion reactions.